Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) has announced management's participation in key investor conferences this September. The biotechnology company focuses on developing innovative treatments by correcting abnormal gene expression, particularly in oncology. The upcoming conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 13. Webcasts of these events will be available on their website for 90 days post-conference.

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in upcoming investor conferences in September. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Morgan Stanley 20^th Annual Global Healthcare Conference 
Monday, September 12, 2022, at 8:45 a.m. ET
Please find a link to the fireside chat here

H.C. Wainwright 24^th Annual Global Investment Conference 
Tuesday, September 13, 2022, at 10:00 a.m. ET
Please find a link to the presentation here

A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days.

About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com 

Michael Lampe, ScientPR (Media)
michael@scientpr.com 

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

FAQ

What investor conferences is Foghorn Therapeutics (FHTX) attending in September 2022?

Foghorn Therapeutics will attend the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

What time is Foghorn Therapeutics' presentation at the H.C. Wainwright Conference?

Foghorn Therapeutics' presentation at the H.C. Wainwright Conference is scheduled for September 13, 2022, at 10:00 a.m. ET.

Where can I access the webcasts of Foghorn Therapeutics' conference presentations?

Webcasts of Foghorn Therapeutics' conference presentations will be available on their website under 'Events & Presentations' for up to 90 days.

What is the focus of Foghorn Therapeutics' research?

Foghorn Therapeutics focuses on correcting abnormal gene expression to develop new treatments, particularly in oncology.

What is Foghorn Therapeutics' Gene Traffic Control platform?

The Gene Traffic Control platform is Foghorn Therapeutics' proprietary system for discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system.